Literature DB >> 29498027

Trading Health Risks for Glory: A Reformulation of the Goldman Dilemma.

Juan Marcos González1, F Reed Johnson2, Matthew Fedoruk3, Joshua Posner4, Larry Bowers5.   

Abstract

BACKGROUND: The Goldman dilemma presented athletes with a Faustian bargain that guaranteed winning an Olympic gold medal in their sport but resulted in certain death 5 years later. Athletes' responses to Goldman's bargain were reported from 1982 to 1995. Several studies subsequently evaluated people's willingness to accept the bargain proposed in the Goldman question. Our study updates Goldman's question using contingent-behavior questions, a preference-elicitation method widely applied in economics, marketing and psychology to understand people's choice behavior. Contingent-behavior questions ask people to evaluate hypothetical tradeoffs between outcomes when real-world decisions are unobservable, nonexistent, or unreliable.
METHODS: A web-enabled survey was conducted with athletes in 50 sports between June, 2012 and April, 2013. Athletes were invited by their sport governing bodies in the United States to complete the online survey. Responses from 2888 athletes were collected. Our reformulation elicited athletes' willingness to accept a performance-enhancing drug (PED) associated with the risk of a realistic fatal event, not certain death. A double-bounded dichotomous-choice question format was used to elicit athletes' maximum acceptable mortality risk (MAMR) for winning an Olympic gold medal. Data were analyzed using an interval regression model to estimate the implicit probability of accepting a continuous risk level. MAMR was defined as the mortality risk level with a 0.50 probability of acceptance.
RESULTS: Estimated mean MAMRs varied between 7 and 14% across athletes in different ranks and sports. Elite athletes were generally the most willing to accept a fatal cardiovascular risk to win a gold medal in the Olympics. This range was similar to the levels of risk that patients accept for life-changing interventions.
CONCLUSIONS: Results suggest that very few athletes would be expected to accept a PED in the bargain postulated by the Goldman dilemma. Risk tolerance among elite athletes suggest they may be more aware of the potential financial and nonfinancial benefits of such a win, and/or less optimistic about their potential to move up in the level of competition without the use of PEDs.

Entities:  

Mesh:

Year:  2018        PMID: 29498027     DOI: 10.1007/s40279-018-0881-9

Source DB:  PubMed          Journal:  Sports Med        ISSN: 0112-1642            Impact factor:   11.136


  12 in total

1.  Design techniques for stated preference methods in health economics.

Authors:  Fredrik Carlsson; Peter Martinsson
Journal:  Health Econ       Date:  2003-04       Impact factor: 3.046

Review 2.  Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics.

Authors:  John F P Bridges
Journal:  Appl Health Econ Health Policy       Date:  2003       Impact factor: 2.561

3.  Would you dope? A general population test of the Goldman dilemma.

Authors:  J M Connor; J Mazanov
Journal:  Br J Sports Med       Date:  2009-02-11       Impact factor: 13.800

Review 4.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

5.  Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis.

Authors:  Leslie S Wilson; Aimee Loucks; Gregory Gipson; Lixian Zhong; Christine Bui; Elizabeth Miller; Mary Owen; Daniel Pelletier; Douglas Goodin; Emmanuelle Waubant; Charles E McCulloch
Journal:  Int J MS Care       Date:  2015 Mar-Apr

6.  Incorporating patient-preference evidence into regulatory decision making.

Authors:  Martin P Ho; Juan Marcos Gonzalez; Herbert P Lerner; Carolyn Y Neuland; Joyce M Whang; Michelle McMurry-Heath; A Brett Hauber; Telba Irony
Journal:  Surg Endosc       Date:  2015-01-01       Impact factor: 4.584

7.  Willingness to accept risk in the treatment of rheumatic disease.

Authors:  B J O'Brien; J Elswood; A Calin
Journal:  J Epidemiol Community Health       Date:  1990-09       Impact factor: 3.710

Review 8.  Anabolic steroids and cardiovascular risk.

Authors:  Peter Angell; Neil Chester; Danny Green; John Somauroo; Greg Whyte; Keith George
Journal:  Sports Med       Date:  2012-02-01       Impact factor: 11.136

Review 9.  Performance enhancing drug abuse and cardiovascular risk in athletes: implications for the clinician.

Authors:  Peter J Angell; Neil Chester; Nick Sculthorpe; Greg Whyte; Keith George; John Somauroo
Journal:  Br J Sports Med       Date:  2012-11       Impact factor: 13.800

Review 10.  Growth hormone and the heart.

Authors:  L Saccà; A Cittadini; S Fazio
Journal:  Endocr Rev       Date:  1994-10       Impact factor: 19.871

View more
  2 in total

1.  Direct Analysis of Doping Agents in Raw Urine Using Hydrophobic Paper Spray Mass Spectrometry.

Authors:  Eduardo Luiz Rossini; Dmytro S Kulyk; Emelia Ansu-Gyeabourh; Taghi Sahraeian; Helena Redigolo Pezza; Abraham K Badu-Tawiah
Journal:  J Am Soc Mass Spectrom       Date:  2020-05-14       Impact factor: 3.109

2.  Do Former Elite Athletes Live Longer? New Evidence From German Olympic Athletes and a First Model Description.

Authors:  Lutz Thieme; Michael Fröhlich
Journal:  Front Sports Act Living       Date:  2020-11-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.